Navigation Links
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
Date:11/3/2008

o Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to relating to the potential efficacy of R788, as well as Rigel's plans to pursue clinical development of R788 and other product candidates, and the timing thereof, the market opportunity for its product candidates, expansion of and changes in its product portfolio and its plans to pursue collaboration partnerships for product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "potential," "intends," "indicates," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the clinical testing and approval process and R
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
3. Rigel to Present at BIO CEO & Investor Conference
4. Rigel Announces Pricing of Public Offering of Common Stock
5. Rigel to Present Research Programs at Scientific Conferences
6. Rigel to Present at BIO Investor Forum 2007
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
9. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
10. Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer
11. BMP Sunstone Announces Participation in November Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... University of the Negev,s Prof. Ron Folman has been named as ... Laser Science and Quantum Optics. The award is presented ... in honor of Willis E. Lamb Jr., who was the 1955 ... physicist and a member of BGU,s Ilse Katz Institute for Nanoscale ...
... Reportlinker.com announces that a new market research report ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of a ... and evaluated as an indicator of normal biological or ...
... NEW YORK, Nov. 9, 2010 NeoStem, Inc. (NYSE Amex: ... biopharmaceutical company with operations in the U.S. and China, today ... M.D., MBA, will be honored tonight at Moves Magazine,s 2010 ... at the Astor Center, 399 Lafayette Street, New York City. ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards 2
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
(Date:8/29/2014)... U.S. Ebola researcher from the University of Texas Medical Branch ... of three monoclonal antibodies can completely protect monkeys against a ... infection, at a time when the disease is severe. , ... editorial for Nature discussing advances in Ebola treatment ... are among the most deadly of pathogens, with fatality rates ...
(Date:8/29/2014)... German . ... nitrogen cycle on Earth and in biological wastewater treatment ... depend on nitrite as their source of energy. An ... microbiologist at the University of Vienna, has now shown ... source of energy. The oxidation of hydrogen with oxygen ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... Calif. How much calcium could a hibernating woodchuck,s ... could sequester calcium? More than enough, it turns out, ... heart rhythms such as ventricular tachycardia and ventricular fibrillation ... to a new study of the hibernating animals that ...
... eluded vaccine-makers for thirty years, in part due to ... clinical virologists from the Massachusetts Institute of Technology (MIT) ... a promising strategy for vaccine design using a mathematical ... to quantum physics, as well as in analyses of ...
... restaurant menus might meet federal labeling requirements but don,t do ... meal choices, a new Columbia University School of Nursing (CUSON) ... NP, DNSc, assistant professor of nursing at CUSON, and colleagues, ... Journal of Urban Health . The researchers studied the calorie ...
Cached Biology News:Woodchucks and sudden cardiac death 2Vaccines for HIV: A new design strategy 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 3
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Mycoplasma and virus tested...
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... Clone/PAD: 3F10B10. Immunogen: Synthetic ... region of JAB1 (Jun activation ... Specificity: Specific for the JAB1 ... controls: 293T Jurkat cell lysates). ...
Biology Products: